Literature DB >> 30363414

Olfactory Impairment Predicts Underlying Dopaminergic Deficit in Presumed Drug-Induced Parkinsonism.

James F Morley1,2, Gang Cheng3,4, Jacob G Dubroff3,4, Stephanie Wood1, Jayne R Wilkinson1,2, John E Duda1,2.   

Abstract

Drug-induced parkinsonism (DIP) is common, and the motor symptoms can be indistinguishable from Parkinson's disease (PD). When symptoms persist after drug withdrawal, this may represent "unmasking" of underlying PD. We previously reported that hyposmia, a common nonmotor feature of PD, was associated with persistent DIP. Here, we report on a series of 33 consecutive patients who underwent dopamine transporter imaging to evaluate DIP. We examined the clinical correlates of underlying dopaminergic denervation by comparing subjects with normal and abnormal scans. Imaging was abnormal in 7 of 33 (21%) cases. Motor features were similar in patients with normal and abnormal scans. Olfactory testing was available for 30 subjects and was concordant with imaging in 27 of 30 (odds ratio = 63; 95% confidence interval: 4.8-820; P = 0.002). Olfactory testing may be a simple screen to help identify DIP patients with underlying dopaminergic denervation, consistent with unmasking of incipient PD.

Entities:  

Keywords:  antipsychotic; dopamine transporter SPECT imaging; olfaction; secondary parkinsonism

Year:  2016        PMID: 30363414      PMCID: PMC6174443          DOI: 10.1002/mdc3.12458

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  16 in total

Review 1.  Olfactory dysfunction in schizophrenia: a qualitative and quantitative review.

Authors:  P J Moberg; R Agrin; R E Gur; R C Gur; B I Turetsky; R L Doty
Journal:  Neuropsychopharmacology       Date:  1999-09       Impact factor: 7.853

2.  Persistent drug-induced parkinsonism.

Authors:  T A Aronson
Journal:  Biol Psychiatry       Date:  1985-07       Impact factor: 13.382

3.  Clinical characteristics of neuroleptic-induced parkinsonism.

Authors:  S Hassin-Baer; P Sirota; A D Korczyn; T A Treves; B Epstein; H Shabtai; T Martin; Y Litvinjuk; N Giladi
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

4.  Reversible drug-induced parkinsonism. Clinicopathologic study of two cases.

Authors:  A H Rajput; B Rozdilsky; O Hornykiewicz; K Shannak; T Lee; P Seeman
Journal:  Arch Neurol       Date:  1982-10

Review 5.  The role of DAT-SPECT in movement disorders.

Authors:  G Kägi; K P Bhatia; E Tolosa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-01       Impact factor: 10.154

6.  Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?

Authors:  T T Lim; A Ahmed; I Itin; M Gostkowski; J Rudolph; S Cooper; H H Fernandez
Journal:  Int J Neurosci       Date:  2013-01-04       Impact factor: 2.292

7.  Neuroleptic-induced parkinsonism is associated with olfactory dysfunction.

Authors:  Stephanie Krüger; Antje Haehner; Claudia Thiem; Thomas Hummel
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

8.  Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.

Authors:  Francisco J Diaz-Corrales; Salome Sanz-Viedma; David Garcia-Solis; Teresa Escobar-Delgado; Pablo Mir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

9.  Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambuí study).

Authors:  Maira Tonidandel Barbosa; Paulo Caramelli; Débora Palma Maia; Mauro César Quintão Cunningham; Henrique Leonardo Guerra; Maria Fernanda Lima-Costa; Francisco Cardoso
Journal:  Mov Disord       Date:  2006-06       Impact factor: 10.338

10.  Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.

Authors:  Michele Tinazzi; Angelo Antonini; Tommaso Bovi; Isabella Pasquin; Maria Steinmayr; Giuseppe Moretto; Antonio Fiaschi; Sarah Ottaviani
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

View more
  3 in total

Review 1.  Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease.

Authors:  Michelle E Fullard; James F Morley; John E Duda
Journal:  Neurosci Bull       Date:  2017-08-22       Impact factor: 5.203

2.  Olfactory Testing in Parkinson Disease and REM Behavior Disorder: A Machine Learning Approach.

Authors:  Christine Lo; Siddharth Arora; Yoav Ben-Shlomo; Thomas R Barber; Michael Lawton; Johannes C Klein; Sofia Kanavou; Annette Janzen; Elisabeth Sittig; Wolfgang H Oertel; Donald G Grosset; Michele T Hu
Journal:  Neurology       Date:  2021-02-24       Impact factor: 9.910

3.  Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism.

Authors:  Whitley W Aamodt; Jacob G Dubroff; Gang Cheng; Betty Taylor; Stephanie Wood; John E Duda; James F Morley
Journal:  NPJ Parkinsons Dis       Date:  2022-04-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.